9 studies were found.

1.		No longer recruiting	Cisplatin Plus Bryostatin 1 in Treating Patients With Advanced Cancer Condition: unspecified adult solid tumor, protocol specific
2.		No longer recruiting	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer Conditions: recurrent ovarian epithelial cancer; stage III ovarian epithelial cancer; stage IV ovarian epithelial cancer
3.		No longer recruiting	Doxorubicin and Paclitaxel in Treating Women With Locally Advanced Breast Cancer Conditions: stage IIIB breast cancer; stage IIIA breast cancer
4.		Recruiting	Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer Condition: unspecified adult solid tumor, protocol specific
5.		Recruiting	Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer Conditions: stage I breast cancer; stage II breast cancer; stage IIIA breast cancer; stage IIIB breast cancer; stage IIIC breast cancer; stage IV breast cancer
6.		Recruiting	Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer Conditions: Colon Cancer; Non-small cell lung cancer; Rectal Cancer; Small Cell Lung Cancer
7.		No longer recruiting	Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer Condition: unspecified adult solid tumor, protocol specific
8.		No longer recruiting	Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors Conditions: stage IIIB non-small cell lung cancer; stage III pancreatic cancer; stage IV breast cancer; stage IIIA non-small cell lung cancer; ...
9.		No longer recruiting	VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin Condition: unspecified adult solid tumor, protocol specific